The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Open accessAbstract
CD4(+) T cells contribute to tumor eradication, even in the absence of CD8(+) T cells. Cytotoxic CD4(+) T cells can directly kill MHC class II positive tumor cells. More surprisingly, CD4(+) T cells can indirectly eliminate tumor cells that lack MHC class II expression. Here, we review the mechanisms of direct and indirect CD4(+) T cell-mediated elimination of tumor cells. An emphasis is put on T cell receptor (TCR) transgenic models, where anti-tumor responses of naïve CD4(+) T cells of defined specificity can be tracked. Some generalizations can tentatively be made. For both MHCII(POS) and MHCII(NEG) tumors, presentation of tumor-specific antigen by host antigen-presenting cells (APCs) appears to be required for CD4(+) T cell priming. This has been extensively studied in a myeloma model (MOPC315), where host APCs in tumor-draining lymph nodes are primed with secreted tumor antigen. Upon antigen recognition, naïve CD4(+) T cells differentiate into Th1 cells and migrate to the tumor. At the tumor site, the mechanisms for elimination of MHCII(POS) and MHCII(NEG) tumor cells differ. In a TCR-transgenic B16 melanoma model, MHCII(POS) melanoma cells are directly killed by cytotoxic CD4(+) T cells in a perforin/granzyme B-dependent manner. By contrast, MHCII(NEG) myeloma cells are killed by IFN-γ stimulated M1-like macrophages. In summary, while the priming phase of CD4(+) T cells appears similar for MHCII(POS) and MHCII(NEG) tumors, the killing mechanisms are different. Unresolved issues and directions for future research are addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITA
Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B., & Mach, B. (1994) · Science · doi:10.1126/science.8016643 · Cited by 898
Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898
Effector T cell plasticity: flexibility in the face of changing circumstances
Murphy, K. M., & Stockinger, B. (2010) · Nature Immunology · doi:10.1038/ni.1899 · Cited by 482
Primary Antitumor Immune Response Mediated by CD4+ T Cells
Corthay, A., Skovseth, D. K., Lundin, K. U., Røsjø, E., Omholt, H., Hofgaard, P. O., Haraldsen, G., & Bogen, B. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.003 · Cited by 478
Self-citation
Cited by
Saha, D., Martuza, R. L., & Rabkin, S. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.006 · Cited by 591
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Axelrod, M. L., Cook, R. S., Johnson, D. B., & Balko, J. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3200 · Cited by 490
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
Wolf, Y., Bartok, O., Patkar, S., Eli, G. B., Cohen, S., Litchfield, K., Levy, R., Jiménez-Sánchez, A., Trabish, S., Lee, J. S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.032 · Cited by 380
Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead
Oiseth, S. J., & Aziz, M. S. (2017) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.41 · Cited by 369
Single-cell transcriptomics reveals expansion of cytotoxic CD4 T cells in supercentenarians
Hashimoto, K., Kouno, T., Ikawa, T., Hayatsu, N., Miyajima, Y., Yabukami, H., Terooatea, T., Sasaki, T., Suzuki, T., Valentine, M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907883116 · Cited by 343
Metadata
- Authors
- Haabeth, O. A. W., Tveita, A. A., Fauskanger, M., Schjesvold, F., Lorvik, K. B., Hofgaard, P. O., Omholt, H., Munthe, L. A., Dembic, Z., Corthay, A., & Bogen, B.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2014-04-15
- Volume
- 5
- Pages
- 174-174
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2130621814
- Cited by
- 202
- References
- 8
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? https://app.cochat.ai/papers/10.3389/fimmu.2014.00174
- The paper
- Haabeth, O. A. W., Tveita, A. A., Fauskanger, M., Schjesvold, F., Lorvik, K. B., Hofgaard, P. O., Omholt, H., Munthe, L. A., Dembic, Z., Corthay, A., & Bogen, B. (2014). How Do CD4+ T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Frontiers in Immunology. https://doi.org/10.3389/fimmu.2014.00174
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.